Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer, effective 31 January 2024.
Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer, effective 31 January 2024.